

In the

Supreme Court of the United States

SECURITIES AND EXCHANGE COMMISSION,)

Petitioner.)

vs.)

MEDICAL COMMITTEE FOR HUMAN RIGHTS,)

Respondent.)

No. 70-61

Washington, D. C.

November 10, 1971

Pages 1 thru 42

RECEIVED
SUPREME COURT, U.S.
MARSHALLS OFFICE
NOV 18 4 07 PM '71

HOOVER REPORTING COMPANY, INC.

Official Reporters
Washington, D. C.

546-6666

IN THE SUPREME COURT OF THE UNITED STATES

----- X
SECURITIES AND EXCHANGE COMMISSION, :

Petitioner, :

-v. :

No. 70-61

MEDICAL COMMITTEE FOR HUMAN RIGHTS, :

Respondent. :

----- X
Washington, D. C.,

Wednesday, November 10, 1971.

The above-entitled matter came on for argument at

1:01 o'clock, p.m.

BEFORE:

WARREN E. BURGER, Chief Justice of the United States
WILLIAM O. DOUGLAS, Associate Justice
WILLIAM J. BRENNAN, JR., Associate Justice
POTTER STEWART, Associate Justice
BYRON R. WHITE, Associate Justice
THURGOOD MARSHALL, Associate Justice
HARRY A. BLACKMUN, Associate Justice

APPEARANCES:

ERWIN N. GRISWOLD, ESQ., Solicitor General, for
the Petitioner.

ROBERTS B. OWEN, ESQ., 888 Sixteenth Street, N. W.,
Washington, D. C. 20006, for the Respondent.

C O N T E N T SORAL ARGUMENT OF:PAGE

Erwin N. Griswold, Esq.,
for the Petitioner

3

Roberts B. Owen, Esq.,
for the Respondent

20

P R O C E E D I N G S

MR. CHIEF JUSTICE BURGER: We will hear arguments in No. 61, Securities and Exchange Commission against the Medical Committee for Human Rights.

Mr. Solicitor General.

ORAL ARGUMENT OF ERWIN N. GRISWOLD, ESQ.,

ON BEHALF OF THE PETITIONER

MR. GRISWOLD: May it please the Court:

This case comes here on a writ of certiorari to the United States Court of Appeals for the District of Columbia Circuit. It arises under Section 14(a) of the Securities Exchange Act of 1934 relating to proxy solicitation, and under the regulations under that Act; and it raises questions of the reviewability of action or nonaction of the Commission with respect to proxy materials.

The text of Section 14(a) is printed on page 49 of the Commission's brief. It makes it unlawful to use the facilities of the mails or of interstate commerce or of an exchange in contravention of such rules and regulations as the Commission may prescribe as necessary or appropriate in the public interest or for the protection of investors to solicit or permit the use of his name to solicit any proxy or consent with respect to any security.

But that is simply a delegation to the Commission to make rules with respect to proxies in the public interest or

for the protection of investors.

And at this point I would also like to bring to the Court's attention Section 21(e) of the Securities Exchange Act of '34, which is also printed on page 49 of the government's brief, which authorizes the Commission, whenever it appears that there is a violation of the Act or about to be a violation of the Act, it may in its discretion bring an action in the appropriate United States District Court.

Finally, I would call attention to the regulations which the Commission has made under Section 14(a), specifically those relating to proposals of security holders, which is Rule 14(a)-8 of the Commission's rules; that is rather long, but it is set out in full on page 51 to 55 of the Commission's brief.

With this as the legal setting, I turn to the facts.

The respondent here is the Medical Committee on Human Rights. The record does not show whether it is a corporation or a voluntary association, nor does it show how the committee is made up, or how its spokesmen are authorized.

The record does show that early in 1968 it acquired, by gift, five shares of the common stock of Dow Chemical Corporation, a Delaware corporation.

Even before the shares were registered in its name, it made a request on the company to include a proposal in its proxy material for the 1968 annual meeting of Dow. That

request related to the sale of napalm by Dow. But it came too late for action at the 1968 meeting.

Early in 1969 the Medical Committee sent a new request to Dow, asking that there be submitted to the Dow shareholders, in Dow's proxy solicitation for the 1969 annual meeting, a proposal requesting that the company's charter be amended with respect to the sale of napalm.

That appears on pages 10 and 12 of the Appendix.

On the advice of its general counsel, Dow decided to omit the proposal. In accordance with Rule 14(a)-8(d), Dow notified both the Committee and the Commission of its decision, stating its reasons and including an opinion of counsel as required by the rule.

The Committee then modified its proposal so that it would propose a resolution which would amend the company's by-laws so as to prohibit the manufacture of napalm, and asked the Commission staff to review the matter.

On February 16th, 1969, the Commission's staff informed the Committee and Dow that it would not recommend any action to the Commission if the proposal was omitted from Dow's proxy material.

The Committee's counsel then asked that the Commission itself review the staff's position. And on March 24th, 1969, the Commission, as shown by its minute book, quote, "determined to raise no objection to the omission from the management's

proxy statement of certain resolutions proposed by the Medical Committee for Human Rights."

Now, I would suggest this is a little like a denial of writ of certiorari by this Court, which amounts to a statement that this Court will take no action with respect to a decision below and is not in any way a decision by this Court as to the merits of the case.

On May 29th, 66 days after the Commission's no-action determination, the Committee filed a petition for review of the Commission's action in the United States Court of Appeals for the District of Columbia Circuit, and this brings us to a threshold difficulty with the case.

The statute under which this proceeding was brought, Section 25(a) of the Securities Exchange Act, printed on page 50 of the Commission's brief, provides that a petition for review may be filed "within 60 days after the entry of such order".

Q Mr. Solicitor General, I'm curious. This is brought up only in the Reply Brief, is it not?

MR. GRISWOLD: It was referred to in the main brief. I suggest that it is jurisdictional, and I simply want to submit it for the Court's consideration on that basis. It is certainly novel to say that an order is not entered until written notice of it is given. Here notice was given by telephone on the day the order was entered. There is no requirement with respect

to this Court's judgment or with respect to the judgments that this Court reviews, that the date of entry of the order, and, after all, that's what Congress said was the entry of the order, is deferred until written notice is given, and if it is jurisdictional, it seems to me appropriate that I should lay it before the Court for its consideration.

But assuming that there is jurisdiction, we come to the questions of administrative law which have been briefed by the parties. These are discussed at length in the principal briefs which have been filed. The argument can become rather extensive and complex, and this has been developed fully, and I hope carefully, in our briefs. I hope, for the convenience of the Court.

In this oral argument I want to try to focus on two aspects which seem to me to be of particular importance. The real controversy underlying this case is between the Medical Committee and Dow Chemical Company. Yet Dow is not a party here, and will not be bound by the decision of this Court.

The Commission has no machinery to adjudicate proxy disputes. Nor could it, as a practical matter, adjudicate such disputes within the very short time available during the proxy season. Actually, the Commission's staff reviews something like 5,000 sets of proxy material per year, mostly within a period of three months, in the early part of the year.

Necessarily, the work is largely done by the staff

of the Commission. It is truly a matter of administration. I think it fair to say that the Securities and Exchange Commission has a relatively high reputation for the quality of its work, and it may well be because of the capacity it has shown to develop these administrative activities within the framework of its establishment.

Only a few matters can be referred to the Commission itself. Neither the staff nor the Commission has power to issue any orders with respect to proxy. Nor can the Court of Appeals below direct the Commission to take any affirmative action with respect to proxy matters. By the very terms of the statute, that is committed to the Commission "in its discretion".

All that the Court of Appeals has purported to do here is to require the Commission to make a statement with respect to a question of law which would not necessarily control the Commission's action. Indeed, the Medical Committee now urges in its brief, at page 21 that its petition for review sought to review only "the legal determination" that it presumes the Commission made when it declined to institute an enforcement action.

And that, I think, is a little bit like asking this Court to certify what its view was as to the merits of a case, when it denied -- denies certiorari.

Q Mr. Solicitor General, would it make any difference if the parties could go to the District Court and

ask for an injunction?

MR. GRISWOLD: That --

Q Or do you think they could?

MR. GRISWOLD: Well, that is the remedy, Mr. Justice. The Medical Committee was entirely free to go to the District Court and seek an order on Dow Chemical Company which could then be litigated with those two parties; that, under Delaware law, it was required to submit this and that under the proxy rules of the Commission that it was required to submit these.

Q So that their claim would be that the proxy material was not adequate?

MR. GRISWOLD: Whose claim would be?

Q The Medical Committee, if it went to the District Court. They would claim that the proxy material was not adequate.

MR. GRISWOLD: The Medical Committee's claim would be that the proxy material was adequate and was required to be submitted to the shareholders.

Q Well, I mean the proxy that was sent out, or --

MR. GRISWOLD: That the proxy that Dow had sent out was not adequate; yes, Mr. Justice.

Q But in the sense that it didn't disclose what it should have disclosed?

MR. GRISWOLD: And that would raise the questions under both State law and under the proxy rules, which would be subject

to consideration by the Court and another remedy available to the Medical Committee is to send out its own proxy materials, at its own expense; a large part of the problem here is simply who's going to pay for it.

The Medical Committee is entitled, under the proxy rules, to get a list of the shareholders and to mail out its own proxy material and get its proxies and present them and vote them at the meeting, and no one raises any question about that.

Q So the government isn't contending that the Committee doesn't have standing or doesn't have a case of controversy with Dow under the statute, nor that there wouldn't be a federal question in District Court?

MR. GRISWOLD: There may well be a case of controversy with Dow, but it isn't here, because --

Q Yes.

MR. GRISWOLD: -- Dow isn't in this case.

Q So it's a question of which court should it be in, and it's a question of reviewability?

MR. GRISWOLD: It is in part whether the remedy lies in the District Court, as provided in the statute, or, to put the same thing another way, whether it is appropriate for the Court of Appeals to seek to review something or other here under a petition for review under Section 25(a).

What the Medical Committee now seeks is a declaration,

unrelated to relief, and to the only justiciable controversy that has ever existed in this matter, that is between the Medical Committee and Dow.

Now, the only place where the Medical Committee can get that relief is in the State courts of Delaware or in the appropriate district court under Section 27.

Q Well, does the SEC regulations or procedures provide for securing any kind of declaratory relief?

MR. GRISWOLD: Provide for -- I'm sorry, Mr. Justice?

Q For getting any kind of declaratory relief?

MR. GRISWOLD: None whatever, Mr. Justice, that I know of.

Q There is no way that Dow, for example, can come in and say, We want a declaratory order as to the adequacy of proxy --

MR. GRISWOLD: I suppose Dow could come in, but the Commission could properly dismiss that on the ground that there's no provision in the statute for such a procedure.

Q And there's nothing in the regulations which would --

MR. GRISWOLD: Nothing in the regulations which would authorize that.

Now, let me go on to show the attenuated nature of the Medical Committee's position, which I think is shown very clearly by these facts.

The proposal was initially submitted for the annual meeting of Dow in May 1969. That meeting was held two and a half years ago, prior to the filing of the petition for review.

And, second, subsequent to the filing of the petition for review, Dow ceased to manufacture napalm for the government. Does not now manufacture it and has no plans for continuing to do so.

And, third, finally Dow did include the Medical Committee's resolution in Dow's proxy statement for its annual meeting in May 1971. The proposal received less than three percent of the vote of all the shareholders.

Under Rule 14(a)-8(c)(4)(i) of the proxy rules, Dow may exclude this proposal from its proxy materials for the next three calendar years. Thus the issue cannot arise again until 1975.

The question whether the Medical Committee will make similar proposals at that time, and how Dow will treat them, are entirely speculative.

Thus the Medical Committee has obtained everything it sought in this litigation. That is, the distribution of its proposal by Dow at Dow's expense, to enable the security holders to vote on it. All that it seeks now is a declaration that it was entitled to get what it has already received. And giving such a declaration after the event is not the proper function of federal courts in our constitutional system.

Even if there were a live controversy remaining here, the judgment of the court below would be wrong in our submission. The basic question is one of separation of powers or, more accurately, of allocation of powers. We submit that the administration of the proxy regulations is a matter which Congress has committed to the administrative process without provision for, or expectation of, judicial review as to the administrative action.

Not all issues arising in our governmental operation have to be decided by courts. And where the problem is really one of administration, Congress may well choose to allocate it for administrative handling. It remains, of course, subject to the continued review of Congress, through changes in the applicable statute, a review which Congress has never found it necessary to exercise in this area over more than 35 years.

That Congress deliberately decided to allocate this matter to administrative handling without court review is, I submit, shown by the language which Congress used in the statute. Section 14(a) of the Act laid down no rules, I repeat, laid down no rules with respect to proxies. Instead it allocated the area to the Commission. Congress made it illegal to use the facilities of interstate commerce to solicit proxies contrary to "such rules and regulations as the Commission may prescribe".

The rules are the Commission's, by a complete

delegation and clearly intended allocation by Congress.

In an area so amorphous it seems reasonably clear that Congress allocated to the Commission not only the making of the rules and regulations, but also the function of determining their administration and their enforcement in concrete cases.

Q Well, this sounds as though, Mr. Solicitor General, you would think that in allocating this job to the Commission that Congress didn't intend any party to have a cause of action in the District Court --

MR. GRISWOLD: No, Mr. Justice, not at all.

Q All right.

MR. GRISWOLD: The cause of action in the District Court remains, but it is in no sense a review of the Commission's action.

Q All right. Thank you.

MR. GRISWOLD: And the cause of action in the District Court is largely based on State law, and Congress was deliberately not enacting a federal corporation law, it was deliberately leaving these, the underlying problems here, to the laws of the States. Congress was simply taking action to provide for the protection of investors, and assigning to the Commission the function of seeing to it that appropriate steps were taken for the protection of investors.

Q So you're suggesting, then, that if the Medical Committee could have gone to the District Court, it wouldn't

have been going there under the federal question jurisdiction. And it could not assert a cause of action under the federal statute.

MR. GRISWOLD: On the contrary, Mr. Justice, I think the Medical Committee had two choices. It could have gone into the Delaware State courts as a matter of State law, making no reference to the federal statute.

On the other hand, it could have gone into the appropriate District Court, which I assume is Delaware, but I haven't checked that, relying on the proxy rules of the Commission and also on the State law, in which case the statute provides that the District Court shall have exclusive jurisdiction to enforce these provisions.

Q And their claim would be that under federal law the proxy that's sent out must be adequate? Is that it?

MR. GRISWOLD: That would be the claim, yes. But they are -- what we're really saying is that they are not entitled to have the support of the Commission in that suit.

Q Well, what if Dow had completely ignored the -- had never submitted anything to the Commission and purported -- although there had been submissions to it by the Medical Committee, and they started to send out the proxies. I suppose the Medical Committee, under -- could go into the District Court and say the procedures haven't been complied with?

MR. GRISWOLD: The Medical Committee could itself

sue, and I would think that under those circumstances it would be very likely that the Commission would pick up the ball and carry it itself and bring the suit, with the Medical Committee perhaps as a party.

Q Do you think the Commission has authority to go into court for an injunction to enjoin the inadequate proxies --

MR. GRISWOLD: Oh, there isn't the slightest --

Q There's no question about that?

MR. GRISWOLD: There isn't the slightest doubt of that, Section 25 provides that the Commission "in its discretion" may bring a suit to enforce the statute --

Q Yes.

MR. GRISWOLD: -- or the regulation. But I --

Q Could I -- excuse me, did I interrupt you?

MR. GRISWOLD: Well, all I'm saying is I don't think that the Commission is under any obligation to bring such a suit if, in its discretion, it thinks it should not.

Q I think I detected in Mr. Justice White's question something of the case where the Commission was asked to exercise its discretion and declined to do anything. What would be the remedy if they paid no attention to a request?

MR. GRISWOLD: The remedy would be to bring a suit in the United States -- for the Medical Committee to bring a suit in the United States District Court.

Q To require them to exercise --

MR. GRISWOLD: To require -- not -- not against the Commission, no; against Dow. To require Dow to comply with (a) the State law and (b) with the proxy rules.

Q But no procedure against the Commission to require it to exercise its statutory duty, its discretionary duty?

MR. GRISWOLD: I was -- you changed, Mr. Chief Justice. There is no statutory duty. There is a duty to exercise its discretion. There isn't the slightest doubt that it did exercise its discretion here, adversely.

Q Well, I was assuming a case where it refused to do anything. It did not exercise its discretion at all.

MR. GRISWOLD: Well, that would be another case, Mr. Chief Justice, if the Commission refused to do anything. That would be an extraordinarily negative-negative order, I suppose. But might be, might conceivably be subject to review as an utter abuse of discretion.

There's no suggestion here that anything of that sort occurred.

If all questions under the proxy rules are subject to review by the Courts, then they must be handled differently, as I've already said they are very numerous. If they're subject to review, there must be a thorough record, there must be reasoned opinions, there must be a clear opportunity for

intra-Commission review, for all of which there is no time. I think it was Emerson who said that the central tragedy of life is that there are only 24 hours in a day.

Congress may well have thought it better for the whole matter to be handled by the administrative process, without judicial review.

And support for this is found in other provisions of the statute. The allocation of the area to the Commission in 14(a). It's found in the fact that Congress made no provision for any order by the Commission in the area. And it's found, finally, that it expressly allocated the enforcement of these provisions to the Commission in its discretion.

There is no provision that this essentially administrative determination shall be made by the courts, or even that the court shall have power to review the Commission's action or inaction, unless it shall appear to the Commission that there is about to be a violation, and the Commission, in its discretion, brings an action in the proper court.

We think that this comes within the -- well within the language which the Court used in the case of Schilling v. Rogers in 363 U.S., cited on pages 39 and 40, of our brief.

There are many reasons why the Commission might conclude that it would take no action, not every case taken to a court will be decided by that court, as is evident in this Court's certiorari jurisdiction.

Another analogy that naturally occurred to me is that not every case can be taken to a court, even though there may be a basis for thinking the decision is wrong and that there should be review, as is evident in the function of the Solicitor General to decide what cases to appeal and what cases to bring to this Court on petition for certiorari.

These are discretionary functions, and it would be hard to give a consistently reasoned justification for every decision which frequently turns on other considerations than the merits of the case, and there would not be time to give such reasons if, for some reason, it was thought that it had to be done.

All of this, it seems to me, is nicely exemplified in the present case. The Court of Appeals was not in a position to vindicate any right of the Medical Committee. That can be done only in a District Court, in an action to enforce compliance with the proxy rules. The Court of Appeals cannot order the Commission to seek enforcement. There is no provision for such a mandatory order in Section 25(a), and the decision to seek enforcement has been expressly committed by Congress to the discretion of the Commission.

All that the Court of Appeals can do in this case is to express its view of the law applicable to a controversy between the Medical Committee and Dow that has not been presented by those parties for the court's consideration. And

the decision of the Court of Appeals will not be binding on the District Court if the Medical Committee seeks to enforce there its rights as a shareholder, if for no other reason than that Dow is not a party before the Court of Appeals, and is not in any way bound by its decision.

Thus the present procedural posture of the case shows clearly enough that the only end to which it can come is an advisory opinion by the court below on a matter as to which the court can require no action to be taken and which is one that Congress has expressly allocated for good reason, for handling by the administrative process and not by the courts. And the judgment should be reversed.

MR. CHIEF JUSTICE BURGER: Thank you, Mr. Solicitor General.

Mr. Owen.

ORAL ARGUMENT OF ROBERTS B. OWEN, ESQ.,

ON BEHALF OF THE RESPONDENT

MR. OWEN: Mr. Chief Justice, and may it please the Court:

I want to get to the merits of the issue presented for decision here as quickly as I can, but I think I should deal with one issue at the outset, an issue which was belatedly raised by the government, and which I think deserves immediate attention.

The Court will recall that in the petition for

certiorari the government affirmatively took the position that this case presented an important justiciable controversy which deserved resolution here.

They affirmatively argued in those papers that even if Dow Chemical Company should ultimately include our shareholder proposal in the proxy material, and even if that proposal should thus reach the shareholders and be rejected by those shareholders, nevertheless, this case would not be moot. And they affirmatively argued, we think correctly, that the case involved a continuing controversy between the Medical Committee and the SEC.

Now, in those certiorari papers they cited two decisions of this Court, to the effect that where you have a continuing controversy of this kind, the Court should go forward and decide the question on its merits. We agree that those cases are controlling, and we rely upon them.

Now, against that background, both the government's main brief on the merits and our main brief on the merits were directed exclusively to the merits of the controversy, that is, to the issue of administrative reviewability; we did not discuss the Mouqies point, we didn't have an opportunity to do so.

But five days ago, when the government filed their reply brief, they changed their position, and suggested, for the first time, that the controversy we have here is in fact an

abstract academic disputes. They suggest that the action of the Commission in this case was without the practical consequences which are necessary to render the question justiciable.

And I think that if I can take just a moment to describe how the Securities and Exchange Commission actually handles shareholder disputes of this kind, I can show that what we have here is a hard, live, continuing controversy between these parties, so that a judicial resolution of the issue is entirely appropriate.

Now, in discussing what actually happens in the Commission proceedings, I am going to be emphasizing substance and not form. In a series of decisions of this Court, the Court has made clear that the appropriateness of judicial review of administrative action depends on the realities of what the agency does and not on the labels which the agency appends to it. And that is the spirit in which, I think, this case has to be approached.

Now, what we're talking about here is a very specific, narrow, factual situation. This is a situation where a shareholder of a company has submitted a written proposal to the company and requested the company to include the proposal in its proxy materials pursuant to SEC proxy Rule 14(a)-8. That rule provides that, prima facie, every such proposal must be included in the proxy materials so that the shareholders can ultimately consider it.

The rule goes on to provide certain exceptions under which a specific proposal may be excluded.

Now, we're talking about a situation here where the shareholder has submitted his proposal to the company, and said, I want it included under the general rule requiring inclusion.

And the Commission or -- I'm sorry, the company says in response, No, it falls within one of the exceptions in the proxy rules, and it need not, as a matter of law, be included in our proxy materials, and therefore we do not propose to include it.

Now, at that point you, of course, have a concrete dispute between the shareholder and the company. And what happens next is this: The Commission rules require that that dispute between the shareholder and the company be brought before the agency for its review.

We recognize, of course, that the Commission did not have to promulgate the rules, saying that the parties must bring the suit, the dispute before the agency. But the agency has promulgated that rule. Neither the company nor the shareholder can avoid having their dispute brought before the agency. Both of them have to submit, therefore, to agency review of their problems.

Now, specifically, the rules require that the shareholder's proposal and supporting papers must be sent to

the SEC, and the company must also furnish the agency with a statement of its position, and it must also serve those papers on the shareholders, so the shareholder will know what has happened.

Q Could the company just ignore that, in the sense of defaulting?

MR. OWEN: The company always has the option, Mr. Justice, of simply accepting the proposal and putting it in their proxy material.

Q No, I mean when the protest is made to the Commission. Suppose that the company regards it as so frivolous that they just don't want to bother responding?

MR. OWEN: They have no choice, if the --

Q You mean they must respond?

MR. OWEN: One of two things can happen. When they receive the shareholder proposal, they make a legal judgment as to whether they must include that proposal in their proxy material.

Q Well, let's suppose, for example, the request to put in the proxy was, "Please indicate your choice for president in the next election". They want that put in the proxy statement. Do you mean that the company must respond to that frivolous request?

MR. OWEN: No. If you please, Your Honor, what happens is this: They take that shareholder proposal, however

absurd or valid it may be, they hold it up against the Commission's proxy rules, which say that certain kinds of proposals must be included and certain may be excluded. They make a legal determination for themselves, whether they must include or not, and they make a decision then when they will or will not include.

Now, of course, if they agree to include it, they've done exactly what the shareholder wanted, and that's the end of the matter. No disputes.

If they decide to exclude it, then they must report that decision to the Commission, and that triggers the administrative process which I'm about to describe.

Now, let me make clear what the nature of these disputes is. I think I've already gotten to the core of it. We have one factual survey, which has been made of what happens in the Commission, when these disputes are brought before it under the rules. There is a gentleman named Mr. Clusserath, who spent several years in the SEC's Division of Corporation Finance, and he actually surveyed the papers that are submitted to the Commission, and he surveyed what the Commission did with those papers. And he's reported the facts in a publication upon which both sides rely in this case.

He makes very clear from his survey that virtually every dispute, as framed between the shareholder and the company, and which comes before the agency, is a pure dispute of

law. Just a disagreement as to the meaning of the proxy rules.

The company is arguing the proposal falls within one of the exceptions, which allows us to exclude the proposal; and the shareholder is saying, no, we come within the general rule and not within the exceptions. The proxy rules require the inclusion of our proposal.

Now, the Court, I hope, will bear in mind that during the agency proceeding, under the agency's rules, the company has the burden of persuasion on that issue. It is the principle in the agency that all doubts must be resolved in favor of the shareholder, which is to say, in favor of inclusion of the proposal in the proxy material.

Now, when the legal issue has been posed by the two parties to this dispute before the agency, it is first taken under consideration by the staff, that is the Division of Corporation Finance. And what the division does is make a legal determination: whether the proposal must be included or whether it may be excluded under one of the exceptions.

In this case, for example, the Division of Corporation Finance flatly ruled, as a matter of law, and it's written down in the record, that Dow's legal position was correct, and that the shareholder's contentions of the law were wrong.

The Division then notified both parties that they had decided in favor of the company on the legal issue. And they went on to say, in their letter, that in view of that

legal determination, they would not recommend any action against the company, if the proposal were excluded from the proxy material.

Q That, then, still leaves the option up to the company, does it not?

MR. OWEN: The company is still free to include or exclude. As a matter of practice, it always excludes; once it has been notified by the agency that the agency is not going to take any action.

I will come back to that in a moment and show that when it is in the reverse situation, the company always accepts the proposal and includes it in its proxy material.

Now, following the staff's determination as to this legal issue, the losing party may, if he wishes, ask for the full five-man Commission to review the staff's resolution of the legal issue; and, as a matter of practice, when requested to do so, the Commission does review the staff's action.

I might add, incidentally, that written legal argument is submitted to the Commission by both sides, if they want to. That's what happened in this case. Dow presented, if you will, a brief to the Commission and said, We think we're right on the law, and we can exclude; the shareholder responded with written legal argument and said, We think Dow's wrong on the law, we think they are required as a matter of law to include our proposal in the proxy material.

So now I come to the vital question in the case, which is: What does the Commission actually do in a dispute of this kind?

Now, the fact is that in practice the Commission actually decides the proper legal issue on its merits. It takes the shareholder proposal, which is involved, it holds it up against the very precise legal standards which are written out in the Commission's own rules, and it decides the legal status, if you will, of that particular proposal.

And if you look at page 25 of the government's main brief, you will see confirmed the fact by a former Chairman of the Commission that they decide the status of the proposal under the proxy rules. An essentially legal determination.

I might add that in Mr. Clusserath's survey of this whole situation, he recites decision after decision after decision by the Commission on the merits of the legal issue presented. He doesn't identify a single case in which the Commission did not decide the legal issue on its merits.

Indeed, the government here has not cited a single situation in which the Commission did not decide that question on its merits.

And thus far, I might add, there have been five courts that have considered such Commission action, and they all treated it as a decision by the Commission on the merits of the legal issue presented.

Now, in this case, the government, if I may say so, focuses on form and not substance; they focus on the language of the letter, which then came out of the Commission after they had resolved the issue against us. Now, the language of the letter was that they adopted the recommendation of the Division of Corporation Finance, and on that basis would take no action against Dow.

The emphasis that the government places here is on the no-action language, and they say, or they speculate that possibly the Commission somehow bypassed the legal issue which has been argued to it by the parties, and decided to take no action against Dow without deciding that legal issue.

But I should emphasize they are speculating only, as to what the Commission may have done. The government in this case has never come right out and asserted that the Commission sidestepped the legal issue.

And, in any event, it seems to me that the sidestepping speculation, if you will, is pretty unrealistic. Obviously the Commission is not going to decide whether or not to take action against the company without first deciding whether the company is right on the law or wrong on the law. In fact, as Mr. Clusserath's report makes clear, they always did decide the legal issue; if they decide the company is wrong on the law, they send the company a letter and say, We think you're wrong, we think that the law, that is the proxy rules, require

that you include this proposal in your proxy material.

On the other hand, if they decide the company is right on the law, they send out a no-action letter.

Now, that is what actually happens.

Now, let me talk for a moment about the practical impact upon the parties, when a Commission decision has been rendered.

In a case where the Commission decides that the company is wrong on the legal issue, as a practical matter the shareholder can relax, his worries are over. Faced with that decision by the Commission, the company knows it has two choices: it can either bow to the Commission's ruling on the law and include the proposal in its proxy material; or, on the other hand, it can ignore the Commission's ruling. But if it does so, it faces very severe sanction.

In the first place, in that situation, the Commission can institute an administrative proceeding, looking toward delisting the company's securities for violation of the proxy rule.

Q Isn't that discretionary with the Commission?

MR. OWEN: Entirely so, Mr. Justice. Yes.

I'm not saying that any one of these sanctions must be taken by the Commission, but the company knows they are at hazard, and they run this risk.

Now, one risk is an administrative proceeding against

them for delisting of the securities; another is, in an egregious case, possible criminal prosecution by the Attorney General, at the request of the Commission. But the most likely, as a practical matter, is a civil suit by the Commission against the company for injunctive relief to compel the company to include the proposal in the proxy material.

Q Well, you're talking about practical facts --

MR. OWEN: Indeed.

Q -- of the way this works, and as a matter of practical fact, if the company does get that kind of word from the Commission, it includes the material, doesn't it?

MR. OWEN: Absolutely correct, Mr. Justice. In the entire history of the Securities Act there has only been one company who ever declined to abide by the Commission's ruling. That was Trans-America Corporation, they were promptly sued by the Commission; they lost the case. That was in 1947, more than 20 years ago. No company since that time has ever defied the Commission's ruling.

In other words, no shareholder in history has ever had to take any action to defend his rights, once the Commission has ruled in his favor on that issue. And I suggest that is entirely as it should be, one of the principal responsibilities of the SEC is to serve as the guardian of corporate shareholders.

Now, I have discussed the shareholder who wins before

the Commission, but compare his situation with the fellow who loses.

If the Commission, let us assume erroneously, decides against the shareholder in this dispute, which they have brought before themselves, then of course that shareholder has been wronged, and he suffers a number of distinct -- in a number of distinct practical ways.

In the first place, he has been wrongfully deprived of the Commission's very effective help.

Secondly, if he wants to vindicate his rights, he must undertake the extensive litigation. He has no other choice.

Thirdly, in that litigation, wherever it occurs, the court involved is likely to give great weight, perhaps even decisive weight, to the Commission's ruling, adverse ruling on the question of law involved.

Prior to this case --

Q Mr. Owen --

MR. OWEN: Beg your pardon.

Q -- on what do you base that statement? Isn't that sheer speculation? Isn't it just as likely that the Court of Appeals might do the same thing on the review action, such as this one?

MR. OWEN: I think not, Your Honor. Let me -- as far as a District Court is concerned, let me mention that there have been, before this case, only three lawsuits brought

in District Court. In each case the Commission had ruled adversely to the sheriff, and in each case the Court said, "Ah, you're faced with adverse determination by the Commission, they're an expert body, they've interpreted their own proxy rules; I am going to give great weight to that. I think it is unlikely that you are going to prevail on the merits, and I deny you preliminary injunctive relief."

Q Well, that's --

MR. OWEN: That is invariably so.

Q -- that certainly isn't true -- you're speaking of just three cases. That isn't true as to ICC review. There are many instances where District Courts haven't -- albeit three-judge District Courts -- haven't given automatic approval to an ICC ruling.

MR. OWEN: That is correct, and I suggest, Mr. Justice, that there is a distinction between the situation where the agency, of which complaint is made, is before the Court and is arguing its case, and presenting its position. In a situation like that, the Court is entirely competent to pass on whatever the legal questions will be, or may be presented; and no great weight, then, is going to be given to the administrative interpretation of the law.

But the situation, I suggest, is otherwise, where the Commission is not present. You have District Court litigation between the shareholder and Dow Chemical Company,

all you have is a Commission interpretation of its rules. The District judge, a busy man, being asked to enjoin the shareholders' meeting, or to take some other drastic step, he cannot ask the Commission for its views, he doesn't have them before him in the litigation. He simply accepts the fact that the Commission has interpreted its rules, it has interpreted those rules against the shareholder. He says the Commission's view is entitled to great weight. That's the end of the matter.

Now, that has happened in the only cases that have ever come up in District Court. I don't say that it should happen that way. I am simply saying that that is past history.

Q Mr. Owen, assume, if you could, that the Commission found that the corporation was wrong, and should include the statement. And the corporation didn't include it. Could the proposer of the language get mandamus or some form of action to make the Commission move?

MR. OWEN: I think not. I am --

Q You're sure not, aren't you?

MR. OWEN: Should not, yes, Mr. Justice.

Q I mean, it says within its discretion.

MR. OWEN: That is correct. And we do not say that the shareholder --

Q Well, what you say is, even though you couldn't

make them enforce it, you can make them to decide it; is that your position?

MR. OWEN: Not quite, Mr. Justice.

Our position is that what happens in fact is that the Commission decides the legal issue. Now, at that point, we cannot, and we do not claim the right to require the Commission to take any particular action.

Q Well, the court --

MR. OWEN: But if they have to --

Q -- the court here said that you must make a finding.

MR. OWEN: The Court of Appeals, Mr. Justice, remanded to the Commission simply with the request that they clarify their reasoning; that the Court of Appeals looked at the Commission's reasoning on the merits and said, in effect, we simply don't understand how you could come out that way, and we would like you to clarify your reasoning on the legal issue.

Q Well, what's that --

MR. OWEN: So that if an error of law had been made by the Commission, it could be rectified by the court.

Q How?

MR. OWEN: I beg your pardon, sir?

Q How?

MR. OWEN: It would -- well, let me put it this way:

If the case now goes back, as we think it should, to the Commission, the Commission will then explain how it reached this conclusion. If the Commission says, We find --

Q Then everybody, including the Court and everybody in the United States, disagrees with the reasons, what can you do about it?

MR. OWEN: We could take it back to the Court of Appeals for a declaration of what the law really says. We would not --

Q And what would you get from that?

MR. OWEN: We would get no coercive action at all.

Q What would this Committee get?

MR. OWEN: What this Committee would get is an explanation of the law by the Court of Appeals. That is of the correct legal principles that should govern the Commission. This is --

Q What good would that do?

MR. OWEN: The good that it would do, I submit, is that the Commission would obey, or would follow the principle enunciated by the Court. This is if you --

Q Although it wouldn't need to?

MR. OWEN: It wouldn't need to. But we --

Q It could say, We refuse to follow the Court of Appeals.

MR. OWEN: That's correct.

But, let me --

Q Or it could say, We agree with you, and that's very interesting, but we're not going to do anything about it.

MR. OWEN: That in fact does not happen, and let me remind the Court, if I may, that in such cases as Abbott Laboratories v. Gardner, the only thing that was requested of the Court was a declaratory judgment. That is a declaration of what the law really is. And Abbott Laboratories was content with that relief. They got it. And they got -- it was a very practical remedy.

Let me remind you that in the case of Perkins v. Elg, this was the case where the lady had been denied the passport, and she had suggested that she had been denied that passport -- incidentally, the issuance of passports is a discretionary function -- but the Secretary had denied her the passport because he ruled that she was legally ineligible.

What this Court did was review that legal determination and say, If she's legally eligible, the Secretary can't deny her the passport on that ground. He may be able to deny the passport on some other ground, but not on the basis of a legal error.

It was a declaration, then, of the correct legal principles. It was not a coercive form of decree.

We did not, in the Court of Appeals, ask for a coercive form of decree, and I think this is one of the mis-

understandings we have with the Solicitor General. He suggests that we want to the Court of Appeals and said, We want you, the Court of Appeals, to direct the Commission to start enforcement proceedings against Dow.

That isn't what we did. If you read our petition --

Q Mr. Owen, --

MR. OWEN: Excuse me.

Q -- you've only got about five minutes left.

I hope you're going to save some time to tell us why this is still a live controversy, in light of the action on the proxy statement doing just what you wanted, and in light of the fact that they've stopped manufacturing napalm.

MR. OWEN: Well, I will, Mr. Justice, --

Q I don't want you to run out of time.

MR. OWEN: I thank you for inviting my attention to that.

First of all, the company -- it is not in the record that the company has stopped manufacturing napalm. I gather it is the fact. It is also the fact, not in the record, that they immediately announced that they wanted to get that contract back again and resume supplying napalm to the government.

So that as far as that fact is concerned, I think it is simply beside the point.

Q Was it '71, this year, when they put this

question in the proxy?

MR. OWEN: It was, after we had fought for two years, they finally bowed to the Court of Appeals' view of the law and said, We are reserving all rights to exclude the next time around.

They made it very clear that the next time around they are reserving the right to exclude our proposal on legal grounds.

But this time they put it in the proxy materials.

Now, it is the firm intention of this organization to submit this proposal again. It has an affirmative right to do that under the proxy rules.

Q Only if they're still manufacturing napalm.

MR. OWEN: Or intending to.

Q Well, I might go along with that, but what -- what do we know if they'll be manufacturing in '75?

MR. OWEN: The proposal, as Your Honor is aware, submitted by this shareholder, was that the certificate of incorporation of the company be modified, amended, so as to foreclose it from manufacturing napalm. Now, that's a continuing problem.

The company has publicly announced it intends --

Q Did you get enough votes so that you can put it back in?

MR. OWEN: We are going to resubmit this, probably, let

us say, within 20 months after this Court's decision in this case. Presumably Dow will exclude it once more; presumably the Commission will rule against us, and we will find ourselves in exactly this same controversy again.

Now, the government represented to the Court that this was an important issue of judicial review that was involved. There have been no facts that have come into existence that were not in existence when the government submitted the case to you. And when they briefed it to you.

And we rely on the very cases that they have cited in their papers, that -- to the effect that this case is not moot.

Now, if I may, I would like to spend one moment on the review statute with which we are dealing. That statute says, in effect, that if we were a party to a proceeding before the Commission, if the Commission took final action in our case, and if we were aggrieved by that action, we are affirmatively entitled to judicial review.

I submit that we fall squarely within the language of that statute. We were a party to a proceeding before the Commission. The Commission took final action in our case. They had required us to appear; we didn't want to, but they did. We were aggrieved by that final action, and I suggest that we therefore fall squarely within the terms of the review statute that is presented.

Q How about the -- perhaps you touched on it, but if so I missed it -- the government's point with respect to the time limitation of Section 25(a) of the '34 Act? The 60-day provision.

MR. OWEN: All right. The suggestion being that a telephone call that a staff member made to some representative of the shareholders, the content of which is not disclosed in this record, figured the statutory period for appeal.

Q Well, this says 60 days after the entry of the order, --

MR. OWEN: Right.

Q -- but the government says there was no order.

MR. OWEN: That's right. That's a different issue.

Q That's a different issue, but --

MR. OWEN: Assuming we have an order, the first notice we got of it was when they sent us a letter, except for the phone call.

Q Well, except for the phone call. You did get notice of the phone call?

MR. OWEN: We didn't -- there is nothing in the record to indicate what was said during that phone call. Whether we got an accurate description of the Commission's action or whether we didn't, we waited six days and we got a letter, which told us what the Commission had done. And, with all due respect, I submit that this Court's decision in

Scofield v. The NLRB, in 394 U.S., makes very clear that the aggrieved party is entitled to receive a final definite word as to what's happened to him, before the 60-day period begins to run.

Q I suppose the government would really -- if there's no order, there's no entry, then --

MR. OWEN: That would be correct if there's no order. I think the Red Lion Broadcasting case makes clear that there is an order.

Let me say in conclusion that we are hard-pressed to understand why we should not be entitled to a judicial review in the circumstances of this case. We did not voluntarily present our legal problems to the Commission. The Commission required us to submit to its decision-making process. We following the Commission's rule. The agency then decided that we were legally ineligible to enjoy a right which we think the law has conferred upon us. If that administrative decision was wrong, we have clearly been hurt, and we believe that the courts should be and are available to rectify such errors.

Thank you.

MR. CHIEF JUSTICE BURGER: Thank you, Mr. Owen.

Thank you, Mr. Solicitor General.

The case is submitted.

[Whereupon, at 2:02 p.m., the case was submitted.]